Inari Medical’s (NARI) Neutral Rating Reiterated at Robert W. Baird

Robert W. Baird restated their neutral rating on shares of Inari Medical (NASDAQ:NARI) in a research report released on Tuesday,Benzinga reports. Robert W. Baird currently has a $80.00 price target on the stock, down from their prior price target of $81.00.

Other equities analysts have also issued research reports about the company. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Oppenheimer started coverage on shares of Inari Medical in a research report on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price objective on the stock. Canaccord Genuity Group reissued a “hold” rating and set a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday. Truist Financial lifted their price target on shares of Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Finally, Piper Sandler increased their price objective on Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday, October 29th. Twelve research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $68.00.

Inari Medical Trading Down 0.2 %

Shares of Inari Medical stock opened at $79.30 on Tuesday. Inari Medical has a 12 month low of $36.73 and a 12 month high of $79.69. The stock’s fifty day moving average price is $53.49 and its 200-day moving average price is $49.14. The firm has a market cap of $4.64 billion, a P/E ratio of -58.74 and a beta of 0.97.

Insider Buying and Selling at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the transaction, the director now owns 601,233 shares of the company’s stock, valued at $27,067,509.66. The trade was a 6.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares in the company, valued at approximately $22,265,500. This represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 406,000 shares of company stock worth $22,621,870. Company insiders own 10.60% of the company’s stock.

Institutional Investors Weigh In On Inari Medical

Hedge funds have recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in Inari Medical by 67.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after purchasing an additional 473 shares during the period. KBC Group NV increased its position in shares of Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after buying an additional 498 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in shares of Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after buying an additional 522 shares during the period. Covestor Ltd lifted its position in shares of Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock valued at $99,000 after buying an additional 926 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Inari Medical in the 2nd quarter valued at $104,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.